REGNTICKER
Regeneron Pharmaceuticals, Inc.
Congress has disclosed 37 buys and 38 sells of REGN (Regeneron Pharmaceuticals, Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
37
Buy
38
Sell
-1
Net
19
Active politicians
Round-trip watch Still on the books
Members who disclosed buying REGN and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.
| Member | Entry (last buy) | Entry price | Now | vs entry | Status |
|---|---|---|---|---|---|
| Rohit Khanna | 2026-07-07 | $675.44 | $953.79 | +41.2% | in profit |
| Gilbert Cisneros | 2025-11-18 | $721.64 | $953.79 | +32.2% | in profit |
| Alan Armstrong | 2026-03-27 | $735.75 | $953.79 | +29.6% | in profit |
| Julia Letlow | 2026-02-12 | $780.63 | $953.79 | +22.2% | in profit |
Price as of 2026-11-02. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).
Price & congressional trades
Buy
Sell
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Health. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
P/E
21.05
▼ cheaper than
Health (median 29.7)
how it's calculated
P/E = price ÷ earnings per share
$953.79 ÷ $45.32 = 21.05
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
P/B
3.03
▼ cheaper than
Health (median 4.4)
how it's calculated
P/B = price ÷ book value per share
$953.79 ÷ $315.13 = 3.03
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
EV/EBITDA
18.44
▲ pricier than
Health (median 16.2)
how it's calculated
EV/EBITDA = (market cap + net debt) ÷ EBITDA — net cash lowers EV
($101.4B − $1.7B net cash) ÷ $5.4B = $99.7B ÷ $5.4B = 18.44
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
Legislation Related Legislation
Recent bills in this stock's sector (Health). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.
| Bill | Title | Policy area | Latest action |
|---|---|---|---|
| HR 10887 | Protecting Consumer Access to Generic Drugs Act of 2026 | Health | 2026-10-22 |
| HR 10874 | Medicare Low Income Subsidy Equality Act of 2026 | Health | 2026-10-22 |
| HR 10858 | CARE for Blood Cancer Act of 2026 | Health | 2026-10-22 |
| HR 10810 | National Patient Safety Board Act of 2026 | Health | 2026-10-15 |
| HR 10824 | Stroke Education and EMS Care Improvement Act of 2026 | Health | 2026-10-15 |
75 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2026-07-07 | 27 days | +12.3% | $1K–$15K | 20.2 | ↗ filing |
| Gilbert Cisneros | House | SELL ◆ insider convergence | Self · 150 Main Street Trust > Bank of America | 2026-05-15 | 21 days | -8.9% | $1K–$15K 0.1% of NW |
13.7 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Spouse | 2026-04-13 | 21 days | -5.0% | $1K–$15K | 19.3 | ↗ filing |
| Alan Armstrong | Senate | BUY ◆ insider divergence | Self | 2026-03-27 | 116 days | -8.3% | $1K–$15K | 99.4 | ↗ eFD |
| Julia Letlow | House | BUY ◆ insider divergence | Self · Merrill Lynch Investment Account #025 | 2026-02-12 | 17 days | -0.1% | $1K–$15K 1.0% of NW |
66.4 | ↗ filing |
| Gilbert Cisneros | House | BUY ◆ insider divergence | Self · 150 Main Street Trust > Bank of America | 2025-11-18 | 24 days | +2.3% | $1K–$15K 0.1% of NW |
24.5 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2025-11-03 | 31 days | +12.7% | $1K–$15K | 18.8 | ↗ filing |
| Rohit Khanna | House | BUY OCR | Child | 2025-05-19 | 21 days | -13.1% | $1K–$15K | 19.6 | ↗ filing |
| Rob Bresnahan | House | BUY | Self · JP Morgan Brokerage Account | 2025-05-15 | 0 days | 0.0% | $1K–$15K 0.2% of NW |
25.1 | ↗ filing |
| Byron Donalds | House | SELL | Self · Moran Wealth IRA | 2025-04-10 | 25 days | +10.5% | $1K–$15K 0.3% of NW |
88.6 | ↗ filing |
| Byron Donalds | House | SELL | Spouse · Moran Wealth IRA | 2025-04-10 | 25 days | +10.5% | $1K–$15K 0.3% of NW |
88.6 | ↗ filing |
| Rob Bresnahan | House | SELL | Self · JP Morgan Brokerage Account | 2025-04-08 | 0 days | 0.0% | $1K–$15K 0.2% of NW |
58.7 | ↗ filing |
| Jefferson Shreve | House | SELL | Self · CRT - Standard Unit Trust | 2025-04-07 | 18 days | +5.2% | $15K–$50K <0.1% of NW |
93.8 | ↗ filing |
| Julie Johnson | House | SELL | Joint · Merrill Lynch Tax Efficient Core | 2025-04-01 | 35 days | -9.5% | $1K–$15K <0.1% of NW |
48.9 | ↗ filing |
| Rob Bresnahan | House | SELL | Self · JP Morgan Brokerage Account | 2025-02-25 | 0 days | 0.0% | $1K–$15K 0.2% of NW |
67.0 | ↗ filing |
| Julie Johnson | House | SELL | Joint · Merrill Lynch Tax Efficient Core | 2025-02-12 | 22 days | +5.3% | $1K–$15K <0.1% of NW |
50.7 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint · Morgan Stanley - Select UMA Account # 1 | 2025-01-24 | 13 days | +6.8% | $1K–$15K <0.1% of NW |
5.9 | ↗ filing |
| Julie Johnson | House | BUY | Joint · Merrill Lynch Tax Efficient Core | 2025-01-15 | 23 days | +0.9% | $1K–$15K <0.1% of NW |
66.4 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2024-12-18 | 20 days | +2.2% | $1K–$15K | 26.5 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence | Joint · Morgan Stanley - Select UMA Account # 1 | 2024-11-29 | 4 days | -0.1% | $1K–$15K <0.1% of NW |
5.9 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence | Joint · Morgan Stanley - Select UMA Account # 1 | 2024-11-19 | 14 days | +0.7% | $1K–$15K <0.1% of NW |
5.9 | ↗ filing |
| Jonathan Jackson | House | SELL ◆ insider convergence | Joint · Morgan Stanley Trust Account | 2024-11-13 | 20 days | -6.8% | $15K–$50K 1.1% of NW |
56.6 | ↗ filing |
| Jonathan Jackson | House | SELL ◆ insider convergence | Joint · Morgan Stanley Trust Account | 2024-11-01 | 32 days | -11.1% | $1K–$15K 0.3% of NW |
51.1 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence | Joint · Morgan Stanley - Select UMA Account # 1 | 2024-10-23 | 13 days | -11.9% | $1K–$15K <0.1% of NW |
13.3 | ↗ filing |
| Greg Landsman | House | SELL ◆ insider convergence | Spouse · Sarah Landsman Traditional IRA | 2024-10-15 | 14 days | -8.8% | $1K–$15K 0.6% of NW |
95.2 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence · moderate | Joint · Morgan Stanley - Select UMA Account # 1 | 2024-07-01 | 42 days | — | $1K–$15K <0.1% of NW |
0.2 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence · moderate | Joint · Morgan Stanley - Select UMA Account # 1 | 2024-02-08 | 26 days | — | $1K–$15K <0.1% of NW |
0.2 | ↗ filing |
| Jonathan Jackson | House | BUY ◆ insider divergence · moderate | Joint · Morgan Stanley Trust Account | 2024-01-17 | 19 days | — | $1K–$15K 0.3% of NW |
67.2 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence · moderate | Child | 2024-01-10 | 23 days | — | $1K–$15K | 31.8 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence | Joint · Morgan Stanley - Select UMA Account # 1 | 2023-11-13 | 22 days | — | $1K–$15K <0.1% of NW |
2.6 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2023-11-03 | 32 days | — | $1K–$15K | 40.4 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence · moderate | Child | 2023-08-29 | 7 days | — | $1K–$15K | 93.1 | ↗ filing |
| Josh Gottheimer | House | BUY ◆ insider divergence · moderate | Joint · Morgan Stanley - Select UMA Account # 1 | 2023-08-21 | 17 days | — | $1K–$15K <0.1% of NW |
24.8 | ↗ filing |
| Greg Landsman | House | BUY ◆ insider divergence · moderate | Spouse · Sarah Landsman Traditional IRA | 2023-08-11 | 363 days | — | $1K–$15K 0.6% of NW |
99.7 | ↗ filing |
| Josh Gottheimer | House | BUY ◆ insider divergence · moderate | Joint · Morgan Stanley - Select UMA Account # 1 | 2023-07-11 | 28 days | — | $1K–$15K <0.1% of NW |
2.6 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence | Joint · Morgan Stanley - Select UMA Account # 1 | 2023-06-22 | 14 days | — | $1K–$15K <0.1% of NW |
2.6 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence | Joint · Morgan Stanley - Select UMA Account # 1 | 2023-03-06 | 31 days | — | $1K–$15K <0.1% of NW |
2.6 | ↗ filing |
| Josh Gottheimer | House | BUY | Joint · Morgan Stanley - Select UMA Account # 1 | 2022-10-19 | 15 days | — | $1K–$15K <0.1% of NW |
2.6 | ↗ filing |
| Josh Gottheimer | House | BUY | Joint · Morgan Stanley - Select UMA Account # 1 | 2022-09-12 | 23 days | — | $1K–$15K <0.1% of NW |
4.5 | ↗ filing |
| Josh Gottheimer | House | BUY | Joint · Morgan Stanley - Select UMA Account # 1 | 2022-05-05 | 34 days | — | $1K–$15K <0.1% of NW |
5.5 | ↗ filing |
| Donald Sternoff Beyer | House | SELL | Joint | 2022-02-28 | 1 days | — | $1K–$15K <0.1% of NW |
6.8 | ↗ filing |
| Donald Sternoff Beyer | House | BUY | Joint | 2021-09-17 | 2 days | — | $1K–$15K <0.1% of NW |
8.6 | ↗ filing |
| Donald Sternoff Beyer | House | BUY | Joint | 2021-07-21 | 4 days | — | $1K–$15K <0.1% of NW |
10.6 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint | 2021-07-01 | 36 days | — | $1K–$15K <0.1% of NW |
6.8 | ↗ filing |
| Donald Sternoff Beyer | House | BUY | Joint | 2021-06-17 | 13 days | — | $1K–$15K <0.1% of NW |
15.7 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint | 2021-05-17 | 18 days | — | $1K–$15K <0.1% of NW |
8.6 | ↗ filing |
| Josh Gottheimer | House | BUY | Joint | 2021-01-11 | 25 days | — | $1K–$15K <0.1% of NW |
19.6 | ↗ filing |
| Gilbert Cisneros | House | BUY | Self | 2020-12-22 | 17 days | — | $1K–$15K 0.1% of NW |
52.4 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint | 2020-12-11 | 25 days | — | $1K–$15K <0.1% of NW |
15.7 | ↗ filing |
| Donald Sternoff Beyer | House | SELL | Joint | 2020-08-14 | 20 days | — | $1K–$15K <0.1% of NW |
22.3 | ↗ filing |
| Donald Sternoff Beyer | House | SELL | Joint | 2020-07-10 | 22 days | — | $1K–$15K <0.1% of NW |
40.4 | ↗ filing |
| Josh Gottheimer | House | BUY | Joint | 2020-05-27 | 12 days | — | $1K–$15K <0.1% of NW |
31.8 | ↗ filing |
| Donald Sternoff Beyer | House | BUY | Joint | 2020-05-20 | 11 days | — | $1K–$15K <0.1% of NW |
86.8 | ↗ filing |
| Dean Phillips | House | SELL | Self | 2020-05-13 | 28 days | — | $1K–$15K <0.1% of NW |
8.6 | ↗ filing |
| Dean Phillips | House | SELL | Self | 2020-04-02 | 34 days | — | $1K–$15K <0.1% of NW |
10.6 | ↗ filing |
| Mikie Sherrill | House | SELL | Self | 2020-02-20 | 12 days | — | $1K–$15K 0.1% of NW |
22.3 | ↗ filing |
| Mikie Sherrill | House | BUY | Self | 2020-01-15 | 23 days | — | $1K–$15K 0.1% of NW |
40.4 | ↗ filing |
| Mikie Sherrill | House | SELL | Self | 2019-12-12 | 22 days | — | $1K–$15K 0.1% of NW |
75.9 | ↗ filing |
| Josh Gottheimer | House | BUY | Joint | 2019-11-01 | 33 days | — | $1K–$15K <0.1% of NW |
40.4 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint | 2019-09-20 | 17 days | — | $1K–$15K <0.1% of NW |
75.9 | ↗ filing |
| Dean Phillips | House | BUY | Self | 2019-09-11 | 27 days | — | $1K–$15K <0.1% of NW |
26.5 | ↗ filing |
| Gilbert Cisneros | House | BUY | Self | 2019-08-14 | 27 days | — | $1K–$15K 0.1% of NW |
86.8 | ↗ filing |
| Dean Phillips | House | BUY | Self | 2019-08-13 | 27 days | — | $1K–$15K <0.1% of NW |
31.8 | ↗ filing |
| Dean Phillips | House | SELL | Self | 2019-05-13 | 25 days | — | $1K–$15K <0.1% of NW |
40.4 | ↗ filing |
| Thomas Suozzi | House | BUY | Self | 2019-05-02 | 28 days | — | $50K–$100K 0.7% of NW |
61.4 | ↗ filing |
| Nicholas Taylor | House | SELL | Spouse | 2019-03-25 | 0 days | — | $15K–$50K | 30.7 | ↗ filing |
| Nicholas Taylor | House | SELL | Spouse | 2019-03-07 | 0 days | — | $1K–$15K | 22.3 | ↗ filing |
| Nicholas Taylor | House | SELL | Spouse | 2019-02-06 | 0 days | — | $1K–$15K | 40.4 | ↗ filing |
| Nicholas Taylor | House | SELL | Spouse | 2019-01-22 | 0 days | — | $1K–$15K | 75.9 | ↗ filing |
| Dean Phillips | House | BUY | Self | 2019-01-04 | 32 days | — | $1K–$15K <0.1% of NW |
75.9 | ↗ filing |
| Thomas Suozzi | House | BUY | Self | 2018-11-05 | 25 days | — | $15K–$50K 0.3% of NW |
90.9 | ↗ filing |
| Gary Palmer | House | SELL | Spouse | 2018-09-18 | 0 days | — | $1K–$15K 0.3% of NW |
98.8 | ↗ filing |
| Michael Conaway | House | SELL | Spouse | 2016-01-28 | 5 days | — | $1K–$15K | 40.4 | ↗ filing |
| Steve Chabot | House | BUY | Self | 2015-05-26 | 0 days | — | $1K–$15K | 84.9 | ↗ filing |
| Michael Conaway | House | BUY | Spouse | 2015-02-09 | 3 days | — | $1K–$15K | 75.9 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in REGN — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
12
Congress trades with insider convergence
14
…with insider divergence
697
Insider open-market trades
Of the congressional trades in REGN, 12 coincided with corporate insiders moving the same way within 60 days, and 14 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-10-30 | BROWN MICHAEL S | Director | SELL 10b5-1 | $1.7M | ↗ EDGAR |
| 2026-10-30 | McCourt Marion | Other | SELL 10b5-1 | $984K | ↗ EDGAR |
| 2026-10-30 | Guarini Kathryn | Director | SELL 10b5-1 | $360K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $5K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $26K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $12K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $18K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $11K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $56K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $21K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $42K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $19K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $167K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $207K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $214K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $147K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $81K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $98K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $9K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $218K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $163K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $173K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $94K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $292K | ↗ EDGAR |
| 2026-10-14 | MURPHY ANDREW J | C-suite | SELL 10b5-1 | $51K | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| ◆ insider | 2026-10-30 | BROWN MICHAEL S Director 10b5-1 | SELL | $1.7M |
| ◆ insider | 2026-10-30 | McCourt Marion Other 10b5-1 | SELL | $984K |
| ◆ insider | 2026-10-30 | Guarini Kathryn Director 10b5-1 | SELL | $360K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $5K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $26K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $12K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $18K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $11K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $56K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $21K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $42K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $19K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $167K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $207K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $214K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $147K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $81K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $98K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $9K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $218K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $163K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $173K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $94K |
| ◆ insider | 2026-10-14 | MURPHY ANDREW J C-suite 10b5-1 | SELL | $292K |
FAQ Common questions
How much has Congress traded REGN?
37 disclosed buys and 38 sells of REGN (Regeneron Pharmaceuticals, Inc.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade REGN?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.